It is now over two years since OAM began. Yet to date, no evaluation of an alternative treatment has been completed. Evaluations of antineoplastons, shark cartilage, the Revici method, and bee pollen are moving so slowly that it often appears nothing is happening. This is troubling. Congress set up this ofÞce to investigate and validate alternative treatments for cancer and other major diseases. Instead, weve gotten conferences, meetings, and a plan, unapproved by the advisory board, to give away money to so-called "centers of excellence" in academia.
Will all this activity answer the burning questions of our movement, e.g., do the various alternative treatments really work? Delays are very demoralizing to staff and advisors alike. The alternative-using public is growing weary of what it sees as bureaucratic delays.
So, daunting questions confront AMPAC as it holds its long-awaited Þrst meeting:
The 18 advisors serve on AMPAC to Þght for the interests of patients. The people want to know the truth about various alternative treatments. AMPAC members should demand serious Þeld trials now, so that the vision we had two years ago can Þnally become a reality.
###